Dermal Cell News Volume 12.09 | May 25 2026

    0
    24







    2026-05-25 | DCN 12.09


    Dermal Cell News by STEMCELL Technologies
    Vol. 12.09 – 25 May, 2026

    TOP STORY

    A MAFG~MITF Complex Drives Melanoma Phenotype Switching and Progression

    Scientists identified the small MAF family transcription factor MAFG as a critical regulator of MITF activity and melanoma cell state plasticity.
    [Nature Communications]

    Abstract
    PUBLICATIONSListed by the impact factor of the journal

    H3K9me3 Controls Epidermis Morphogenesis by Regulating RNA Pol II Dynamics at Developmental Promoters and Enhancers

    Investigators showed that H3K9me3 deposition is dynamic during epidermis morphogenesis and essential for lineage diversification.
    [Nature Communications]

    Abstract

    Rapid Human Skin Barrier Disruption by Sodium Dodecyl Sulfate and Associated Molecular Mechanisms

    Short-term sodium dodecyl sulfate exposure rapidly disrupts human skin barrier integrity through oxidative stress-driven suppression of structural/immune mediators and activation of stress/remodeling pathways.
    [Allergy]

    Full ArticleGraphical Abstract

    Single-Cell RNA-Sequencing of Dermal Fibroblasts Demonstrates Culture-Induced Changes and Variable Persistence of Keloid Disease Features

    Researchers provided a greater understanding of, and potential strategies to refine, essential human fibroblast culture models.
    [iScience]

    Full ArticleGraphical Abstract

    Genetic Drivers of Sensitivity or Resistance to RAS(ON) Multi-Selective Inhibitors in NRAS-Mutated Melanoma

    The authors found that both compounds demonstrated potent anti-proliferative activity against NRAS-mutated melanoma cell lines and robust anti-tumor activity against preclinical melanoma models.
    [Cancer Research]

    Abstract

    Phase I/II Study of Pegenzileukin, a Pegylated Recombinant Non-Alpha IL-2, with Cemiplimab for the Treatment of Advanced Unresectable, or Metastatic Skin Cancers

    Scientists evaluated drug combinations in patients with metastatic melanoma and cutaneous squamous cell carcinoma. Pegenzileukin was given at two dose levels during dose escalation and the recommended Phase II dose during dose expansion, while cemiplimab was given at a dose of 350 mg.
    [Journal for Immunotherapy of Cancer]

    Full Article

    GSDME Acts as an Epigenetic Modifier to Promote Melanoma Development via Centriole Biogenesis Regulator PLK4

    Researchers demonstrated a novel facet of GSDME as an epigenetic modifier that promotes melanoma development through the regulation of the centriole biogenesis regulator PLK4.
    [Cell Death & Differentiation]

    Abstract
    Learn about key considerations for using EasySepâ„¢ products and tips & tricks to avoid the most commonly made mistakes.
    REVIEWS

    The Orchestrated Network of Skin Photoaging: From Intercellular Crosstalk to Molecular Signaling

    The authors systematically elaborate the cellular and molecular mechanisms underlying skin photoaging. This review also details the pivotal roles of and reciprocal crosstalk among fibroblasts, keratinocytes, melanocytes, and various immune cells.
    [Bioscience Trends]

    Abstract
    INDUSTRY AND POLICY NEWS

    Abeona Therapeutics® Announces Activation of Children’s Hospital of Philadelphia as a New Qualified Treatment Center for ZEVASKYN®

    Abeona Therapeutics, Inc. announced activation of the Children’s Hospital of Philadelphia as the sixth Qualified Treatment Center for the administration of ZEVASKYN gene-modified cellular sheets.
    [Abeona Therapeutics, Inc.]

    Press Release
    FEATURED EVENT

    ISMB 2026

    July 12-16, 2026
    Washington, DC, United States

    > See All Events

    JOB OPPORTUNITIES

    Research Associate – Surgical Vision and AI

    Imperial College London – London, England, United Kingdom

    Postdoctoral Position – Presynaptic and Peripheral Plasticity

    University Hospital Würzburg – Würzburg, Germany

    Postdoctoral Fellowships – Computational Biology

    The University of Texas MD Anderson Cancer Center – Houston, Texas, United States

    Research Scientist Positions – Cancer and Stem Cell Biology

    University of Virginia – Charlottesville, Virginia, United States

    Full Professorship – Early Cancer Detection

    Heidelberg University – Heidelberg, Germany

    > See All Jobs

    Submit an article, publication, job or event
    Brought to you by
    stemcell-logo-for newsletter-2